Close the acquisition of Teneobio
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 27 Jul 2021
- Due
- 31 Dec 2021
- Delivered
- October 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The acquisition is subject to customary closing conditions, including applicable regulatory approvals and is expected to close in the second half of 2021.”
What we found
Evidence strength A What the grades mean
Amgen successfully completed the acquisition of Teneobio in October 2021, which falls within the second half of 2021 as originally committed.
-
A Amgen Inc. 10-Q filed 2022-04-28
“As of March 31, 2022 and December 31, 2021, our contingent consideration obligations are primarily the result of our acquisition of Teneobio in October 2021” ✓ confirmed on the page
Market reaction: the shares moved -6.5% against the S&P 500 over the three sessions around the disclosure (27 Apr 2022 to 2 May 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Acquisition of Teneobio
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: customary closing conditions; regulatory approvals
- Depends on
- Regulatory, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Amgen Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-AMGN-004194 · Corrections policy